Research and Markets: Company Study of Chongqing Zhifei Biological Products Co., Ltd, 2012 Available Now

<0> Research and Markets: Company Study of Chongqing Zhifei Biological Products Co., Ltd, 2012 Available Now </0>

<0> Research and MarketsLaura Wood, Senior Manager.U.S. Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716Sector: </0>

() has announced the addition of the report to their offering.

Chongqing Zhifei Biological Products Co., Ltd (Code:300122.SZ), hereinafter referred to as Zhifei Biological, was established in 1995 with the registered capital of RMB 360 million. Listed on the GEM in Sep. 2010, Zhifei Biological is mainly engaged in the development and management of biological technology. Its prime operating businesses include the R & D, production and sales of vaccines and biological products.

Its independent products are: Group A and Group C Meningococcal Polysaccharide Conjugate Vaccine, Group ACYW135 Meningococcal Polysaccharide Vaccine, Mycobacterium vaccine for Injection, etc, Vaccae has passed GMP certification on Mar.23, 2011; exclusive purchase agent products are: Hib vaccine, Hepatitis A (Live) Vaccine], etc.

1 Profile

2 Operation

3 Revenue Structure

4 Gross Margin

5 Client

6 R&D and Investment

Selected Charts

For more information visit

Suggested Articles

Tango Therapeutics is ditching its digs in Kendall Square to move into a new building in Boston’s Fenway neighborhood. Third Rock is coming, too.

The Japanese drugmaker pulled the trigger on the deal after getting a look at phase 1 data on the glutenase TAK-062.

Vanda Pharmaceuticals is hoping to try again with an amended trial after its experimental skin drug tradipitant failed a phase 3 test.